DE60324270D1 - Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung - Google Patents

Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung

Info

Publication number
DE60324270D1
DE60324270D1 DE60324270T DE60324270T DE60324270D1 DE 60324270 D1 DE60324270 D1 DE 60324270D1 DE 60324270 T DE60324270 T DE 60324270T DE 60324270 T DE60324270 T DE 60324270T DE 60324270 D1 DE60324270 D1 DE 60324270D1
Authority
DE
Germany
Prior art keywords
methylated
oxynucleotides
oligode
immunostimulating
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60324270T
Other languages
German (de)
English (en)
Inventor
Ying K Tam
Sean Semple
Sandra Klimuk
Ghania Chikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Tekmira Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/290,545 external-priority patent/US20030125292A1/en
Application filed by Tekmira Pharmaceuticals Corp filed Critical Tekmira Pharmaceuticals Corp
Application granted granted Critical
Publication of DE60324270D1 publication Critical patent/DE60324270D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60324270T 2002-05-10 2003-05-12 Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung Expired - Fee Related DE60324270D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37934302P 2002-05-10 2002-05-10
US10/290,545 US20030125292A1 (en) 2001-11-07 2002-11-07 Mucoscal vaccine and methods for using the same
US46064603P 2003-04-04 2003-04-04
PCT/CA2003/000678 WO2003094963A2 (en) 2002-05-10 2003-05-12 Methylated immunostimulatory oligonucleotides and methods of using the same

Publications (1)

Publication Number Publication Date
DE60324270D1 true DE60324270D1 (de) 2008-12-04

Family

ID=29424457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324270T Expired - Fee Related DE60324270D1 (de) 2002-05-10 2003-05-12 Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung

Country Status (10)

Country Link
EP (2) EP1503793A2 (enExample)
JP (2) JP2005532315A (enExample)
CN (1) CN1665531A (enExample)
AT (1) ATE411815T1 (enExample)
AU (2) AU2003229433B2 (enExample)
CA (2) CA2484266A1 (enExample)
DE (1) DE60324270D1 (enExample)
IL (1) IL165107A0 (enExample)
MX (1) MXPA04011127A (enExample)
WO (2) WO2003094828A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EA008777B1 (ru) 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
CN102203618B (zh) 2008-10-30 2014-10-15 郭培宣 用于dna测序和其他用途的膜集成病毒dna包装马达蛋白连接器生物传感器
WO2011037262A1 (ja) 2009-09-28 2011-03-31 シスメックス株式会社 抗メチル化ｄｎａ抗体を産生するハイブリドーマおよびその利用
CN109985234A (zh) * 2019-04-12 2019-07-09 南华大学 一种梅毒螺旋体dna疫苗及其应用
US20230355733A1 (en) * 2020-07-14 2023-11-09 Evaxion Biotech A/S APC targeting units for immunotherapy
CN116602920B (zh) * 2023-04-18 2024-03-19 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3468773B2 (ja) * 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
FI107974B (fi) * 1999-07-14 2001-10-31 Nokia Networks Oy Menetelmä ja järjestelmä tilastointiin puhelinkeskusjärjestelmässä
DE60036950T2 (de) * 1999-08-27 2008-08-07 Inex Pharmaceuticals Corp., Burnaby Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法

Also Published As

Publication number Publication date
CA2485400A1 (en) 2003-11-20
WO2003094828A3 (en) 2004-02-05
CA2484266A1 (en) 2003-11-20
EP1506010A2 (en) 2005-02-16
WO2003094828A2 (en) 2003-11-20
AU2003229434A1 (en) 2003-11-11
EP1503793A2 (en) 2005-02-09
JP2005532315A (ja) 2005-10-27
EP1506010B1 (en) 2008-10-22
AU2003229433A1 (en) 2003-11-11
AU2003229433B2 (en) 2008-04-24
WO2003094963A2 (en) 2003-11-20
JP2005530761A (ja) 2005-10-13
MXPA04011127A (es) 2005-07-01
AU2003229434A8 (en) 2003-11-11
CN1665531A (zh) 2005-09-07
ATE411815T1 (de) 2008-11-15
WO2003094963A3 (en) 2004-02-12
IL165107A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
DE60324270D1 (de) Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung
DE60129593D1 (de) Zusammensetzungen und verfahren zur extraktion einer nukleinsäure
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
EP1630237A3 (en) Isolation of nucleic acid fragments by hybridisation to a solid support
AU2001244677A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
EP1765417A4 (en) MULTIMERS OF OLIGONUCLEOTIDES IMMUNOSTIMULATORS
WO2003006625A3 (en) Nucleotide compositions comprising photocleavable markers and methods of preparation thereof
WO2004053104A3 (en) 5’ cpg nucleic acids and methods of use
EP1589118A3 (en) Methods and compositions for assessing CpG methylation
DE50309432D1 (de) Verfahren zur herstellung von wässrigen dispersionen
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
MX2009009530A (es) Composiciones de acidos nucleicos cerrados bicatenarios.
JP2007509983A5 (enExample)
WO2005065321A3 (en) Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids
MY165006A (en) Method and compositions for producing fatty alcohols
DE602006017192D1 (de) Verfahren zur herstellung von oligonukleotiden
WO2003052132A3 (en) Linear and hairpin oligonucleotide analogues comprising intercalator pseudonucleotides
ATE302786T1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2004015085A3 (en) Method and compositions relating to 5’-chimeric ribonucleic acids
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
AU2003255621A8 (en) Topical use of at least one double-stranded rna oligonucleotide (ds rna)
IL153200A0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
HK1040402A1 (zh) 使用乳粘素(lactadherin)或其變體的的方法及其組合物
BR0210493A (pt) Composição, e, método para remover cerume humano

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee